公开(公告)号：WO2022086854A1

公开(公告)日：2022-04-28

申请号：PCT/US2021/055415

申请日：2021-10-18

Applicant: CAMAS INCORPORATED

Inventor： MITTENESS, Bradley M. ,  SIMPLOT, Scott ,  HAWKINS, Michelle L. ,  ROBLEY, Brian ,  LARSON, Philip ,  HULL, Jason

IPC: A61P11/00 ,  A61P31/14 ,  A61P31/16 ,  C07K14/08 ,  C07K14/165 ,  C07K14/175 ,  C07K14/18 ,  C07K16/02 ,  C07K16/10 ,  C07K16/12 ,  C12N15/40 ,  C12N15/44 ,  C12N15/50 ,  A61K39/02 ,  A61K39/12 ,  A61K39/145 ,  A61K39/215

Abstract: Egg laying birds on egg farms are inoculated with one or more disease antigens from microbial organisms causing infectious diseases. Egg material from the eggs contain one or more avian antibodies against the microbial organisms and these avian antibodies can specifically bind and/or neutralize the microbial organisms upon consumption by individuals in a population. Egg products comprising the one or more avian antibodies are provided to individuals in the population to increase the prevalence of avian antibodies against the microbial organism in the population. The egg products are provided in a variety of formulations for protecting individuals against the disease and/or for reducing the susceptibility for acquiring the disease. Egg products effective against infections of SARS-CoV-2 in individuals and for reducing the incidence of Covid-19 are provided. Methods are provided to decrease the infection rates of infectious diseases in a population of individuals.

公开(公告)号：WO2021226358A1

公开(公告)日：2021-11-11

申请号：PCT/US2021/031127

申请日：2021-05-06

Applicant: CAMAS INCORPORATED

Inventor： SIMPLOT, Scott ,  MITTENESS, Bradley M. ,  HAWKINS, Michelle ,  HULL, Jason ,  ROBLEY, Brian ,  LARSON, Philip ,  BRIELMAIER, Michael ,  WILLAERT, Benjamin ,  HARKINS, Vergene

IPC: A61K39/42 ,  A61P11/00 ,  A61P31/12 ,  C07K16/08

Abstract: Formulations of egg powders with avian antibodies that act as mucosal protectants are provided. The formulations are effective for protecting the mucosal membranes in the pharyngeal area of an individual from viral infections. Formulations effective for reducing infections of SARS-CoV-2 in individuals are provided. Formulations are also effective for reducing transmission of viral disease. The formulations are tablets, candies, gummies, throat lozenges, and powders for administering to the pharyngeal area. Methods for administering the formulations for reducing viral disease such as Covid-19 are disclosed.